DEDHAM, Mass.--(BUSINESS WIRE)--Qlaris Bio, Inc., a clinical‐stage biotechnology company dedicated to developing first‐in‐class therapies for glaucoma, today announced that new data from studies of ...
Quality Life Science lands a private equity investment from Bluejay Capital to expand its pharma logistics footprint across ...
Qlaris Bio has reported positive topline outcomes from two randomised Phase II US trials, Osprey and Apteryx, of QLS 111 in individuals with primary open-angle glaucoma (POAG) and ocular hypertension ...
DEDHAM, Mass.--(BUSINESS WIRE)--Qlaris Bio, Inc., a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced positive topline results from two ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Patients with primary open-angle glaucoma or ocular ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Qlaris Bio raised $24 million during ...
Strategies will focus on public and private companies developing potentially life-changing medical treatments Partnership combines the insights and scale of BlackRock’s active investment platform with ...
Determining whether QLS Holdings Co Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current QLS ...
QLS-111’s novel intraocular pressure-lowering mechanism targeting EVP to be highlighted in an oral presentation and two poster presentations DEDHAM, Mass., June 23, 2025--(BUSINESS WIRE)--Qlaris Bio, ...
QLS-111’s novel intraocular pressure-lowering mechanism targeting EVP to be highlighted in an oral presentation and two poster presentations Qlaris Bio, Inc., a clinical‐stage biotechnology company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback